Veru (VERU) 10-K 16 Dec 24 2024 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2024	Dec. 12, 2024	Mar. 29, 2024
Document Information [Line Items]
Entity Central Index Key	0000863894
Entity Registrant Name	VERU INC.
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Document Type	10-K
Document Annual Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	1-13602
Entity Incorporation, State or Country Code	WI
Entity Tax Identification Number	39-1144397
Entity Address, Address Line One	2916 N. Miami Avenue, Suite 1000
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33127
City Area Code	305
Local Phone Number	509-6897
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	VERU
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 91,600,000
Entity Common Stock, Shares Outstanding		146,383,920
Auditor Firm ID	677
Auditor Name	Cherry Bekaert LLP
Auditor Location	Atlanta, Georgia

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Assets
Cash and cash equivalents	$ 24,916,285	$ 9,625,494
Accounts receivable, net	3,960,305	4,506,508
Inventories, net	4,144,179	6,697,117
Prepaid research and development costs	419,371	1,006,252
Prepaid expenses and other current assets	1,783,084	1,097,851
Total current assets	35,223,224	22,933,222
Plant and equipment, net	1,284,654	1,652,732
Operating lease right-of-use asset	3,561,773	4,332,473
Deferred income taxes	12,340,237	12,707,419
Intangible assets, net	0	5,952
Goodwill	6,878,932	6,878,932
Other assets	1,129,952	1,512,361
Total assets	60,418,772	50,023,091
Liabilities and Stockholders' Equity
Accounts payable	3,036,841	12,931,172
Accrued compensation	4,679,696	990,609
Accrued expenses and other current liabilities	2,060,097	1,987,738
Residual royalty agreement, short-term portion (Note 9)	1,025,837	864,623
Operating lease liability, short-term portion	1,065,497	1,036,590
Total current liabilities	11,867,968	17,810,732
Residual royalty agreement, long-term portion (Note 9)	8,850,792	8,870,136
Operating lease liability, long-term portion	2,921,380	3,634,114
Other liabilities	4,461,920	29,948
Total liabilities	28,102,060	30,344,930
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock, no shares issued and outstanding at September 30, 2024 and 2023, respectively	0	0
Common stock, par value $0.01 per share; 308,000,000 shares authorized, 148,567,624 and 93,966,402 shares issued and 146,383,920 and 91,782,698 shares outstanding at September 30, 2024 and 2023, respectively	1,485,676	939,664
Additional paid-in-capital	333,788,795	283,894,830
Accumulated other comprehensive loss	(581,519)	(581,519)
Accumulated deficit	(294,569,635)	(256,768,209)
Treasury stock, 2,183,704 shares, at cost	(7,806,605)	(7,806,605)
Total stockholders' equity	32,316,712	19,678,161
Total liabilities and stockholders' equity	$ 60,418,772	$ 50,023,091

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2024	Sep. 30, 2023
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	308,000,000	308,000,000
Common stock, issued (in shares)	148,567,624	93,966,402
Common stock, outstanding (in shares)	146,383,920	91,782,698
Treasury stock, at cost (in shares)	2,183,704	2,183,704

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Net revenues	$ 16,886,419	$ 16,296,958
Cost of sales	11,032,442	8,731,030
Gross profit	5,853,977	7,565,928
Operating expenses:
Research and development	12,808,185	51,202,219
Selling, general and administrative	31,184,097	48,057,834
Provision for credit losses	0	3,911,714
Impairment of intangible assets	0	3,900,000
Total operating expenses	43,992,282	107,071,767
Gain on sale of ENTADFI® assets	1,222,908	5,723,623
Operating loss	(36,915,397)	(93,782,216)
Non-operating income (expenses):
Interest expense	(607,470)	(2,427,041)
Change in fair value of derivative liabilities	(239,000)	2,963,000
Change in fair value of equity securities	(176,077)	0
Other income, net	861,619	573,771
Total non-operating income (expenses)	(160,928)	1,109,730
Loss before income taxes	(37,076,325)	(92,672,486)
Income tax expense	725,101	480,206
Net income (loss)	$ (37,801,426)	$ (93,152,692)
Net loss per basic and diluted common shares outstanding (in dollars per share)	$ (0.28)	$ (1.1)
Basic and diluted weighted average common shares outstanding (in shares)	134,875,016	84,973,382

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Lincoln Park Purchase Agreement [Member] Common Stock [Member]	Lincoln Park Purchase Agreement [Member] Additional Paid-in Capital [Member]	Lincoln Park Purchase Agreement [Member] AOCI Attributable to Parent [Member]	Lincoln Park Purchase Agreement [Member] Retained Earnings [Member]	Lincoln Park Purchase Agreement [Member] Treasury Stock, Common [Member]	Lincoln Park Purchase Agreement [Member]	Common Stock Purchase Agreement [Member] Common Stock [Member]	Common Stock Purchase Agreement [Member] Additional Paid-in Capital [Member]	Common Stock Purchase Agreement [Member] AOCI Attributable to Parent [Member]	Common Stock Purchase Agreement [Member] Retained Earnings [Member]	Common Stock Purchase Agreement [Member] Treasury Stock, Common [Member]	Common Stock Purchase Agreement [Member]	Jefferies Sales Agreement [Member] Common Stock [Member]	Jefferies Sales Agreement [Member] Additional Paid-in Capital [Member]	Jefferies Sales Agreement [Member] AOCI Attributable to Parent [Member]	Jefferies Sales Agreement [Member] Retained Earnings [Member]	Jefferies Sales Agreement [Member] Treasury Stock, Common [Member]	Jefferies Sales Agreement [Member]	Frost Gamma Investments Trust Purchase Agreement [Member] Common Stock [Member]	Frost Gamma Investments Trust Purchase Agreement [Member] Additional Paid-in Capital [Member]	Frost Gamma Investments Trust Purchase Agreement [Member] AOCI Attributable to Parent [Member]	Frost Gamma Investments Trust Purchase Agreement [Member] Retained Earnings [Member]	Frost Gamma Investments Trust Purchase Agreement [Member] Treasury Stock, Common [Member]	Frost Gamma Investments Trust Purchase Agreement [Member]	Public Offering [Member] Common Stock [Member]	Public Offering [Member] Additional Paid-in Capital [Member]	Public Offering [Member] AOCI Attributable to Parent [Member]	Public Offering [Member] Retained Earnings [Member]	Public Offering [Member] Treasury Stock, Common [Member]	Public Offering [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Total
Balance (in shares) at Sep. 30, 2022																															82,692,598
Balance at Sep. 30, 2022																															$ 826,926	$ 253,974,032	$ (581,519)	$ (163,615,517)	$ (7,806,605)	$ 82,797,317
Share-based compensation																															$ 0	17,918,603	0	0	0	17,918,603
Issuance of shares pursuant to share-based awards (in shares)																															191,832
Issuance of shares pursuant to share-based awards																															$ 1,918	387,140	0	0	0	389,058
Issuance of shares (in shares)	800,000						4,004,713						1,277,259					1,277,259	5,000,000
Issuance of shares	$ 8,000	$ 1,000,000	$ 0	$ 0	$ 0	$ 1,008,000	$ 40,047	$ 4,806,644				$ 4,846,691	$ 12,773	$ 1,027,548	$ 0	$ 0	$ 0	$ 1,040,321	$ 50,000	$ 4,919,045	$ 0	$ 0	$ 0	$ 4,969,045
Amortization of deferred costs																																(138,182)				(138,182)
Net Income (loss)																															$ 0	0	0	(93,152,692)	0	(93,152,692)
Balance (in shares) at Sep. 30, 2023																															93,966,402
Balance at Sep. 30, 2023																															$ 939,664	283,894,830	(581,519)	(256,768,209)	(7,806,605)	19,678,161
Share-based compensation																															$ 0	13,644,405	0	0	0	13,644,405
Issuance of shares pursuant to share-based awards (in shares)																															2,734
Issuance of shares pursuant to share-based awards																															$ 27	3,253	0	0	0	3,280
Issuance of shares (in shares)							1,800,000						90,156					90,156							52,708,332
Issuance of shares							$ 18,000	$ 1,643,490	$ 0	$ 0	$ 0	$ 1,661,490	$ 902	$ 65,649	$ 0	$ 0	$ 0	$ 66,551							$ 527,083	$ 34,701,481	$ 0	$ 0	$ 0	$ 35,228,564
Amortization of deferred costs																															0	(164,313)	0	0	0	(164,313)
Net Income (loss)																															$ 0	0	0	(37,801,426)	0	(37,801,426)
Balance (in shares) at Sep. 30, 2024																															148,567,624
Balance at Sep. 30, 2024																															$ 1,485,676	$ 333,788,795	$ (581,519)	$ (294,569,635)	$ (7,806,605)	$ 32,316,712

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
OPERATING ACTIVITIES
Net income (loss)	$ (37,801,426)	$ (93,152,692)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	268,177	269,874
Impairment of intangible assets	0	3,900,000
Provision for credit losses	0	3,911,714
Gain on sale of ENTADFI® assets	(1,222,908)	(5,723,623)
Noncash change in right-of-use assets	770,700	741,257
Noncash interest expense, net of interest paid	(97,130)	1,872,223
Share-based compensation	13,644,405	17,918,603
Deferred income taxes	367,182	177,499
Provision for obsolete inventory	1,566,830	185,499
Change in fair value of derivative liabilities	239,000	(2,963,000)
Change in fair value of equity securities	176,077	0
Loss on disposal of fixed assets	184,267	290
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable	546,203	(4,153,327)
Decrease in inventories	986,108	648,628
Decrease in prepaid expenses and other assets	862,039	9,810,245
Decrease in accounts payable	(5,432,411)	(9,072,222)
Increase (decrease) in accrued expenses and other liabilities	3,944,381	(11,717,919)
Decrease in operating lease liabilities	(683,827)	(666,863)
Net cash used in operating activities	(21,682,333)	(88,013,814)
INVESTING ACTIVITIES
Cash proceeds from sale of ENTADFI® assets	304,536	7,000,000
Capital expenditures	(158,322)	(665,700)
Net cash provided by investing activities	146,214	6,334,300
FINANCING ACTIVITIES
Proceeds from stock option exercises	3,280	389,058
Payment of deferred equity financing issuance costs	0	(263,757)
Proceeds from premium finance agreement	0	1,425,174
Installment payments on premium finance agreement	(132,975)	(1,292,199)
Net cash provided by financing activities	36,826,910	11,114,333
Net increase (decrease) in cash and cash equivalents	15,290,791	(70,565,181)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	9,625,494	80,190,675
CASH AND CASH EQUIVALENTS AT END OF YEAR	24,916,285	9,625,494
Supplemental disclosure of cash flow information:
Cash paid for income taxes	368,820	247,361
Cash paid for interest	704,600	554,818
Schedule of non-cash investing and financing activities:
Equity securities received for sale of ENTADFI® assets	918,372	0
Shares issued in connection with common stock purchase agreement	0	1,008,000
Amortization of deferred costs related to common stock purchase agreement	164,313	138,182
Right-of-use assets recorded in exchange for lease liabilities	0	286,815
Public Offering [Member]
FINANCING ACTIVITIES
Proceeds from sale of shares	35,228,564	0
Jefferies Sales Agreement [Member]
FINANCING ACTIVITIES
Proceeds from sale of shares	66,551	1,040,321
Common Stock Purchase Agreement [Member]
FINANCING ACTIVITIES
Proceeds from sale of shares	1,661,490	4,846,691
Frost Gamma Investments Trust Purchase Agreement [Member]
FINANCING ACTIVITIES
Proceeds from sale of shares	$ 0	$ 4,969,045

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Sep. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	9B. None 9C. Not
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 1 - Nature of Business and

Note 1 - Nature of Business and Significant Accounting Policies	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	Note 1 Nature of Business and Significant Accounting Policies Principles of consolidation and nature of operations 1 FC2 Condom/FC2 FC2 December 2021. April 19, 2023. 15 2024 2023 FC2. FC2 Reclassifications no Use of estimates Segments Cash and cash equivalents and concentration three three Investments in equity securities 825, Financial Instruments September 30, 2024 3 Accounts receivable and concentration of credit risk Inventories first first not not The Company capitalizes inventory costs associated with its drug products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Prior to an initial regulatory approval for our drug products under clinical development, we expense costs relating to the production of inventory as research and development expense in the Company’s consolidated statements of operations, in the period incurred. Fixed assets Leases not not Operating lease costs are recognized for fixed lease payments on a straight-line basis over the term of the lease. Finance lease costs are a combination of the amortization expense for the ROU asset and interest expense for the outstanding lease liability using the applicable discount rate. Variable lease payments are recognized when incurred based on occurrence or usage. Short-term leases with an initial term of 12 not Patents and trademarks Goodwill and intangible assets October 31, 2016. not fourth may not Goodwill consists of the cost of an acquired business in excess of the fair value of the net assets acquired. The Company’s goodwill is assigned to the reporting unit that is expected to benefit from the synergies of a business combination. The Company has identified two single first not not may Regarding goodwill, the estimated fair value of a reporting unit is highly sensitive to changes in projections and assumptions; therefore, in some instances changes in these assumptions could potentially lead to impairment. We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing. Changes in these assumptions may not may Intangible assets are highly vulnerable to impairment charges, particularly IPR&D. These assets are initially measured at fair value and therefore any reduction in expectations used in the valuations could potentially lead to impairment. Some of the more common potential risks leading to impairment include competition, earlier than expected loss of exclusivity, pricing pressures, adverse regulatory changes or clinical trial results, delay or failure to obtain regulatory approval, additional development costs, inability to achieve expected synergies, higher operating costs, changes in tax laws and other macro-economic changes. The complexity in estimating the fair value of intangible assets in connection with an impairment test is similar to the initial valuation. During fiscal 2023, 8 September 30, 2024 2023, Deferred financing costs 10 September 30, 2024 2023 Fair value measurements 820 Fair Value Measurements and Disclosures, 820 not not 3 The carrying amounts reported in the accompanying consolidated balance sheets for cash, accounts receivable, accounts payable and other accrued liabilities approximate their fair value based on the short-term nature of these instruments. The carrying value of the residual royalty agreement liabilities, taking into consideration the related derivative instruments, is estimated to approximate fair value. Derivative instruments not not 9. Revenue recognition 4 Research and development costs no no not September 30, 2024 2023 The Company records estimated costs of research and development activities conducted by third third not may Share-based compensation Advertising September 30, 2024 2023 Income taxes 740 not Foreign currency translation and operations October 1, 2009, September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Other comprehensive loss The U.S. parent company and its U.K. subsidiary routinely purchase inventory produced by its Malaysia subsidiary for sale to their respective customers. These intercompany trade accounts are eliminated in consolidation. The Company’s policy and intent is to settle the intercompany trade account on a current basis. Since the U.K. and Malaysia subsidiaries adopted the U.S. dollar as their functional currencies effective October 1, 2009, 2024 2023 Recent accounting pronouncements not November 2023, 2023 07, Segment Reporting (Topic 280 2023 07 2023 07 10 September 30, 2025, 2023 07 In December 2023, 2023 09, Income Taxes (Topic 740 2023 09 September 30, 2026, 2023 09 In November 2024, 2024 03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220 40 2024 03 September 30, 2028, 2024 03 We have reviewed all other recently issued accounting pronouncements and have determined that such standards that are not not not

Note 2 - Going Concern

Note 2 - Going Concern	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 Going Concern The Company is not twelve may not These uncertainties raise substantial doubt regarding our ability to continue as a going concern for a period of twelve not 205 40, twelve

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 3 Fair Value Measurements FASB ASC Topic 820 The three Level 1 Level 2 not Level 3 There were no 1, 2 3 2024 2023 Amounts capitalized as IPR&D are subject to impairment testing until the completion or abandonment of the associated research and development efforts. We use probability-adjusted discounted cash flow calculations using Level 3 second 2023, 8 As of September 30, 2024 2023 3 The Company determines the fair value of hybrid instruments based on available market data using appropriate valuation models, considering all of the rights and obligations of each instrument. The Company estimates the fair value of hybrid instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective of measuring fair value. In selecting the appropriate technique, the Company considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. Estimating the fair value of derivative financial instruments requires the development of significant and subjective estimates that may, The following table provides a reconciliation of the beginning and ending liability balance associated with embedded derivatives measured at fair value using significant unobservable inputs (Level 3 September 30, 2024 2023 2024 2023 Beginning balance $ 1,331,000 $ 4,294,000 Change in fair value of derivative liabilities 239,000 (2,963,000 ) Ending balance $ 1,570,000 $ 1,331,000 The expense or income associated with the change in fair value of the embedded derivatives is presented as a separate line item in the accompanying consolidated statements of operations. The liabilities associated with embedded derivatives represent the fair value of the change of control provisions in the Residual Royalty Agreement. See Note 9 no FC2 2024 2023 FC2 The following table presents quantitative information about the inputs and valuation methodologies used to determine the fair value of the embedded derivatives classified in Level 3 September 30, 2024 2023 Valuation Methodology Significant Unobservable Input 2024 2023 Scenario-Based Estimated change of control dates March 2025 to March 2027 December 2024 to December 2026 Discount rate 12.1% to 12.3% 14.1% to 15.1% Probability of change of control 60% to 90% 20% to 90% The Company also has an investment in equity securities consisting of 142,749 shares of ONCO Common Stock. The Company received 3,000 shares of Series A Convertible Preferred Stock (the “ONCO Preferred Stock”) of ONCO on October 3, 2023 September 30, 2023 15 825. 3 no no October 3, 2023. On September 24, 2024, 1 September 30, 2024 September 30, 2024 September 30, 2024,

Note 4 - Revenue from Contracts

Note 4 - Revenue from Contracts with Customers	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 4 Revenue from Contracts with Customers The Company generates all its revenue from direct product sales. Revenue from direct product sales is generally recognized when the customer obtains control of the product, which occurs at a point in time, and may The amount of consideration the Company ultimately receives varies depending upon sales discounts, and other incentives that the Company may not Product returns are typically not not The Company’s revenue is primarily from sales of FC2 FC2 April 19, 2023. September 30, 2024 2023 2024 2023 FC2 Global public health sector $ 14,485,159 $ 10,460,024 U.S. prescription channel 2,401,260 5,823,921 Total FC2 16,886,419 16,283,945 Other — 13,013 Net revenues $ 16,886,419 $ 16,296,958 The following table presents net revenue by geographic area for the years ended September 30, 2024 2023 2024 2023 United States $ 5,354,090 $ 8,370,202 South Africa 1,902,149 1,941,678 Brazil 2,760,540 * Mozambique 2,172,840 * Other 4,696,800 5,985,078 Net revenues $ 16,886,419 $ 16,296,958 *Less than 10% The Company’s performance obligations consist mainly of transferring control of products identified in the contracts which occurs either when: i) the product is made available to the customer for shipment; ii) the product is shipped via common carrier; or iii) the product is delivered to the customer or distributor, in accordance with the terms of the agreement. Some of the Company’s contracts require the customer to make advanced payments prior to transferring control of the products. These advanced payments create a contract liability for the Company. The balances of the Company’s contract liability, included in accrued expenses and other current liabilities on the accompanying consolidated balances sheets, was approximately $0.4 million and $0.1 million at September 30, 2024 2023 October 1, 2022 The amount of revenue recognized that was included in the contract liabilities and unearned revenues balance at the beginning of the period was $0.1 million and $0.3 million during the years ended September 30, 2024 2023

Note 5 - Accounts Receivable an

Note 5 - Accounts Receivable and Concentration of Credit Risk	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Note 5 Accounts Receivable and Concentration of Credit Risk The Company’s standard credit terms vary from 30 120 may one The components of accounts receivable consist of the following at September 30, 2024 2023 2024 2023 Trade receivables, gross $ 7,897,739 $ 8,445,370 Less: allowance for credit losses (3,923,857 ) (3,923,857 ) Less: allowance for sales returns and payment term discounts (13,577 ) (15,005 ) Accounts receivable, net $ 3,960,305 $ 4,506,508 The opening balance of the Company's net accounts receivable at October 1, 2022 No customer had a current accounts receivable balance that represented 10% September 30, 2024 2023 At September 30, 2024 two 10% September 30, 2023 three 10% For the year ended September 30, 2024 four 10% September 30, 2023 two 10% The Company maintains an allowance for credit losses for estimated losses resulting from the inability of its customers to make required payments on accounts receivable. Management determines the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts. Management also periodically evaluates individual customer receivables and considers a customer’s financial condition, credit history, and the current economic conditions. Accounts receivable are charged-off when deemed uncollectible. During the year ended September 30, 2023, 11 April 18, 2023. The table below summarizes the change in the allowance for credit losses on trade receivables for the years ended September 30, 2024 2023 2024 2023 Beginning balance $ 3,923,857 $ 12,143 Charge-offs, net of recoveries — 3,911,714 Ending balance $ 3,923,857 $ 3,923,857 Recoveries of accounts receivable previously charged-off are recorded when received. In the global public health sector, the Company’s customers are primarily health care distributors, large global agencies, non-government organizations, ministries of health and other governmental agencies which purchase and distribute FC2

Note 6 - Inventories

Note 6 - Inventories	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 6 Inventories Inventories consisted of the following at September 30, 2024 September 30, 2023 2024 2023 Raw material $ 827,582 $ 1,854,810 Work in process 79,181 112,799 Finished goods 4,819,331 4,913,295 Inventories, gross 5,726,094 6,880,904 Less: inventory reserves (1,581,915 ) (183,787 ) Inventories, net $ 4,144,179 $ 6,697,117 The Company recorded a provision for obsolete inventory of $1.6 million and $0.2 million during the years ended September 30, 2024 2023

Note 7 - Property and Equipment

Note 7 - Property and Equipment	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 7 Property and Equipment Property and equipment consisted of the following at September 30, 2024 2023 Estimated Useful Life (years) 2024 2023 Property and equipment: Manufacturing equipment 5 - 8 $ 2,863,792 $ 3,008,122 Office equipment, furniture and fixtures 3 - 10 1,479,193 1,471,870 Leasehold improvements 3 - 8 960,694 960,694 Total property and equipment 5,303,679 5,440,686 Less: accumulated depreciation and amortization (4,019,025 ) (3,787,954 ) Property and equipment, net $ 1,284,654 $ 1,652,732 Depreciation expense for the years ended September 30, 2024 2023 September 30, 2023 not not September 30, 2024

Note 8 - Intangible Assets and

Note 8 - Intangible Assets and Goodwill	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	Note 8 Intangible Assets and Goodwill Intangible Assets Intangible assets included IPR&D and covenants not September 30, 2024, The gross carrying amounts and net book value of intangible assets, which is included in other assets on the accompanying consolidated balance sheet, were as follows at September 30, 2023 Gross Carrying Accumulated Net Book Amount Amortization Value Intangible asset with finite life: Covenants not-to-compete $ 500,000 $ 494,048 $ 5,952 Indefinite-lived intangible assets: Acquired in-process research and development assets — — — Total intangible assets $ 500,000 $ 494,048 $ 5,952 Amortization was recorded on a straight-line basis over seven not September 30, 2023. September 30, 2024 In March 2023, no two two two September 30, 2023. Goodwill The carrying amount of goodwill at September 30, 2024 2023 September 30, 2024 2023 September 30, 2024

Note 9 - Debt

Note 9 - Debt	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 9 Debt SWK Residual Royalty Agreement On March 5, 2018, August 2021, In connection with the Credit Agreement, the Company and the Agent also entered into a Residual Royalty Agreement, dated as of March 5, 2018 FC2. FC2 FC2 x FC2 12 For accounting purposes, the $10.0 million advance under the Credit Agreement was allocated between the Credit Agreement and the Residual Royalty Agreement on a relative fair value basis. A portion of the amount allocated to the Residual Royalty Agreement, equal to the fair value of the change of control provision, was allocated to an embedded derivative liability. The derivative liability is adjusted to fair market value at each reporting period. At September 30, 2024 2023 2024 2023 Residual royalty agreement liability, fair value at inception $ 346,000 $ 346,000 Add: accretion of liability using effective interest rate 12,985,419 12,377,949 Less: cumulative payments (5,024,790 ) (4,320,190 ) Residual royalty agreement liability, excluding embedded derivative liability 8,306,629 8,403,759 Add: embedded derivative liability at fair value (see Note 3) 1,570,000 1,331,000 Total residual royalty agreement liability 9,876,629 9,734,759 Residual royalty agreement liability, short-term portion (1,025,837 ) (864,623 ) Residual royalty agreement liability, long-term portion $ 8,850,792 $ 8,870,136 As the Company has repaid the original principal of $10.0 million advanced in connection with the Credit Agreement and the Residual Royalty Agreement, payments under the Residual Royalty Agreement are classified as interest payments and included in operating activities on the accompanying consolidated statements of cash flows. The short-term portion of the Residual Royalty Agreement liability represents the aggregate of the estimated quarterly royalty payments payable during the 12 Interest expense on the accompanying consolidated statements of operations relates to the accretion of the liability for the Residual Royalty Agreement. The accretion of the liability is based on projected FC2 Premium Finance Agreement On November 1, 2022, eleven December 1, 2022. September 30, 2023 October 2023 September 30, 2024.

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Equity [Text Block]	Note 10 Stockholders Equity Preferred Stock The Company has 5,000,000 shares designated as Class A Preferred Stock with a par value of $0.01 per share. There are 1,040,000 shares of Class A Preferred Stock – Series 1 2 3 4 September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Common Stock We are authorized to issue up to 308,000,000 shares of common stock, $0.01 par value per share. Holders are entitled to one Shelf Registration Statement In March 2023, 3 No. 333 270606 April 14, 2023. September 30, 2024, 10 December 31, 2023 8 February 27, 2024, not 3 No. 333 270606 3 no March 1, 2025, 1A, Common Stock Offering On December 18, 2023, 3 No. 333 270606 Aspire Capital Purchase Agreement On June 26, 2020, During the year ended September 30, 2023, During the 36-month term of the Aspire Purchase Agreement, we sold 4,424,450 shares of common stock to Aspire Capital resulting in proceeds to the Company of $8.4 million. On June 26, 2023, no In consideration for entering into the Aspire Purchase Agreement, concurrently with the execution of the Aspire Purchase Agreement, the Company issued to Aspire Capital 212,130 shares of the Company’s common stock. The shares of common stock issued as consideration were valued at $0.7 million, based on the closing price per share of the Company’s common stock on the date the shares were issued. This amount and related expenses, which totaled approximately $0.7 million, were recorded as deferred costs. The unamortized amount of deferred costs related to the Aspire Purchase Agreement remaining when the agreement terminated was $0.5 million and was expensed at the time of termination. It is included in selling, general and administrative expenses on the accompanying consolidated statement of operations for the year ended September 30, 2023. Private Investment in Public Equity On April 12, 2023, not Lincoln Park Capital Fund LLC Purchase Agreement On May 2, 2023, may may one not December 13, 2023, 3 No. 333 270606 May 3, 2023, December 13, 2023 Under the Lincoln Park Purchase Agreement, the Company has the right, but not 1 not not not three 10 4:00 In addition to Regular Purchases and provided that the Company has directed a Regular Purchase in full, the Company in its sole discretion may three 3 may The purchase price of Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases and the minimum closing sale price for a Regular Purchase will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction occurring during the business days used to compute the purchase price. The aggregate number of shares that the Company can sell to Lincoln Park under the Lincoln Park Purchase Agreement may no no 5635 In consideration for entering into the Lincoln Park Purchase Agreement, concurrently with the execution of the Lincoln Park Purchase Agreement, the Company issued 800,000 shares of the Company’s common stock to Lincoln Park. The shares of common stock issued as consideration were valued at $1.0 million, based on the closing price per share of the Company’s common stock on the date the shares were issued. This amount and related expenses of $57,000, which total approximately $1.1 million, were recorded as deferred costs. We are obligated to issue $1.0 million of shares of the Company’s common stock at the time Lincoln Park’s purchases cumulatively reach an aggregate amount of $50.0 million of Purchase Shares. We sold 1,800,000 and 1,225,000 shares of common stock to Lincoln Park under the Lincoln Park Purchase Agreement during the years ended September 30, 2024 2023 September 30, 2024 2023 March 1, 2025, not At-the-Market Sale Agreement On May 12, 2023, may not 3 No. 333 270606 May 12, 2023. August 19, 2024, September 3, 2024. not We sold 90,156 and 1,277,259 shares of common stock under the Jefferies Sales Agreement during the years ended September 30, 2024 2023 The Company incurred issuance costs related to the Jefferies Sales Agreement of $0.2 million, which were recorded as deferred costs. The unamortized amount of deferred costs remaining when the agreement terminated was $0.2 million and was expensed at the time of termination. It is included in selling, general and administrative expenses on the accompanying consolidated statement of operations for the year ended September 30, 2024. September 30, 2023

Note 11 - Share-based Compensat

Note 11 - Share-based Compensation	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 11 Share-based Compensation We allocate share-based compensation expense to cost of sales, selling, general and administrative expense and research and development expense based on the award holder’s employment function. We recorded income tax benefits for share-based compensation expense of approximately $3.1 million and $4.0 million during the years ended September 30, 2024 2023 September 30, 2024 2023 2024 2023 Cost of sales $ 404,348 $ 361,843 Selling, general and administrative 10,379,520 13,785,067 Research and development 2,860,537 3,771,693 $ 13,644,405 $ 17,918,603 We have issued share-based awards to employees and non-executive directors under the Company’s approved equity plans. Upon the exercise of share-based awards, new shares are issued from authorized common stock. Equity Plans In June 2022, 2022 2018 September 30, 2024 In March 2018, 2018 “2018 March 29, 2022, may 2018 September 30, 2024 2018 In July 2017, 2017 “2017 2017 September 30, 2024 2017 2017 2008 “2008 2008 Stock Options Each option grants the holder the right to purchase from us one three may ten not September 30, 2024 2023 The following table outlines the weighted average assumptions for options granted during fiscal 2024 2023 2024 2023 Weighted Average Assumptions: Expected Volatility 108.97 % 101.37 % Expected Dividend Yield 0.00 % 0.00 % Risk-free Interest Rate 4.44 % 3.92 % Expected Term (in years) 6.0 6.0 Fair Value of Options Granted $ 1.18 $ 5.55 During the years ended September 30, 2024 2023 zero The following table summarizes the stock options outstanding and exercisable at September 30, 2024 Weighted Average Remaining Aggregate Number of Exercise Price Contractual Term Intrinsic Shares Per Share (years) Value Outstanding at September 30, 2023 17,367,643 $ 5.28 Granted 2,467,980 1.40 Exercised (2,734 ) 1.20 Forfeited (1,370,461 ) 7.56 Outstanding at September 30, 2024 18,462,428 $ 4.59 6.32 $ 44,938 Exercisable at September 30, 2024 12,740,284 $ 4.42 5.27 $ — The aggregate intrinsic values in the table above are before income taxes and represent the number of in-the-money options outstanding or exercisable multiplied by the closing price per share of the Company’s common stock on the last trading day of the year ended September 30, 2024 The total intrinsic value of options exercised was approximately $0.5 million during the year ended September 30, 2023 September 30, 2023 September 30, 2024 As of September 30, 2024 Stock Appreciation Rights In fiscal 2017, October 31, 2018. ten 2017 September 30, 2024 2023

Note 12 - Leases

Note 12 - Leases	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 12 Leases The Company has operating leases for its office, manufacturing and warehouse space, and office equipment. The Company has a finance lease for office equipment, furniture, and fixtures. Corporate Headquarters In June 2021, eight March 1, 2022. February 2022. September 30, 2024 2023 Chicago Lease The Company leased approximately 6,600 square feet of office space located in Chicago, Illinois. The Company executed the lease for this office in May 2016, seven November 1, 2016 October 31, 2023. seven November 1, 2016, five June 1, 2017, one June 1, 2017 October 31, 2023. September 1, 2017, October 31, 2023. January 2018 August 2023. September 842. October 31, 2023. International Leases The Company leases approximately 6,400 square feet of office space located in London, England. The lease was effective in August 2020 five three no February 28, 2023. not The Company leases 45,800 square feet of manufacturing and warehouse space in Selangor D.E., Malaysia. The Company executed the lease for this space in August 2019, three September 1, 2019 August 31, 2022. three August 31, 2025. Certain of our lease agreements include variable lease payments for common area maintenance, real estate taxes, and insurance or based on usage for the office equipment leases. The components of the Company’s lease cost were as follows for the years ended September 30, 2024 2023 2024 2023 Operating lease cost $ 1,078,058 $ 1,117,463 Short-term lease cost 42,683 42,809 Variable lease cost 79,066 186,904 Sublease income (15,148 ) (179,378 ) Total lease cost $ 1,184,659 $ 1,167,798 The Company paid cash of $1.0 million and $0.9 million for amounts included in the measurement of operating lease liabilities during the year ended September 30, 2024 2023 September 30, 2024 2023 Other information related to the Company’s leases as of September 30, 2024 2023 2024 2023 Operating Leases Weighted-average remaining lease term 5.0 6.1 Weighted-average discount rate 7.5 % 7.7 % The Company’s lease agreements do not As of September 30, 2024 Operating Leases Fiscal year ended September 30, 2025 $ 1,110,198 2026 801,893 2027 814,728 2028 833,137 2029 856,526 Thereafter 361,270 Total lease payments 4,777,752 Less imputed interest (790,875 ) Total lease liabilities $ 3,986,877 The Company does not not September 30, 2024 The lease liabilities presented above do not not

Note 13 - Contingent Liabilitie

Note 13 - Contingent Liabilities	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13 Contingent Liabilities The testing, manufacturing and marketing of consumer products by the Company entail an inherent risk that product liability claims will be asserted against the Company. The Company maintains product liability insurance coverage for claims arising from the use of its products. The coverage amount is currently $10.0 million. Litigation On December 5, 2022, No. 1:22 23960 September 15, 2023 19 March 1, 2021 March 2, 2023 10 20 1934 10b 5 On July 7, 2023, No. 2023 019406 01 On September 1, 2023, No. 2:23 01164 November 8, 2023, On September 28, 2023, No. 2:23 01291 November 8, 2023, On October 9, 2023, No. 1:23 23846 On September 30, 2024, June No. 3:24 00676 The Ewing Lawsuit, Maglia Lawsuit, Franchi Lawsuit, Renbarger Lawsuit, Alshourbagy Lawsuit and Ovadias Lawsuit are collectively referred to as the “Shareholder Litigation.” At this time, the Company is unable to estimate potential losses, if any, related to the Shareholder Litigation. License and Purchase Agreements From time to time, we license or purchase rights to technology or intellectual property from third may not not Collaborative Arrangements On January 31, 2022, no 2 August 22, 2024 The terms of the Lilly Agreement met the criteria under ASC Topic 808, 808” 808 not not 606, 730, no Resolution of Commercial Dispute A supplier claimed that we owed approximately $10 million for products and services relating to our efforts to commercialize sabizabulin under an EUA. We disputed the amount owed and on February 29, 2024, December 31, 2025 may April 2024 September 2024. December 31, 2025, January 2026. September 30, 2024 September 30, 2024

Note 14 - Income Taxes

Note 14 - Income Taxes	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 14 Income Taxes The Company accounts for income taxes using the liability method, which requires the recognition of deferred tax assets or liabilities for the tax-effected temporary differences between the financial reporting and tax bases of its assets and liabilities, and for net operating loss (NOL) and tax credit carryforwards. Within the calculation of the Company’s annual effective tax rate the Company has used assumptions and estimates that may The Company completes a detailed analysis of its deferred income tax valuation allowances on an annual basis or more frequently if information comes to its attention that would indicate that a revision to its estimates is necessary. In evaluating the Company’s ability to realize its deferred tax assets, management considers all available positive and negative evidence on a country-by-country basis, including past operating results, forecasts of future taxable income, and the potential Section 382 2024 two not September 30, 2024 September 30, 2024 September 30, 2024 2023 September 30, 2024 2023 not may 20 September 30, 2024 2023 As of September 30, 2024 2025 2044 2038 2044. September 30, 2024 Loss before income taxes was taxed by the following jurisdictions for the years ended September 30, 2024 2023 2024 2023 Domestic $ (37,791,920 ) $ (90,522,387 ) Foreign 715,595 (2,150,099 ) Total $ (37,076,325 ) $ (92,672,486 ) A reconciliation between the effective tax rate and the U.S. statutory rate and the related income tax expense is as follows: 2024 2023 Amount Tax Rate Amount Tax Rate Income tax benefit at U.S. federal statutory rates $ (7,786,028 ) 21.0 % $ (19,461,222 ) 21.0 % State income tax benefit, net of federal benefits (602,861 ) 1.6 (1,506,855 ) 1.6 Non-deductible expenses 200,233 (0.5 ) 330,281 (0.3 ) U.S. research and development tax credit 655,526 (1.8 ) 178,378 (0.2 ) Effect of foreign income tax rates 292,970 (0.8 ) 454,808 (0.5 ) Effect of common stock options exercised 13,339 0.0 180,847 (0.2 ) Effect of global intangible low-taxed income 500,613 (1.4 ) (24,691 ) (0.0 ) Change in valuation allowance 7,367,014 (19.9 ) 20,205,808 (21.8 ) Other, net 84,295 (0.2 ) 122,852 (0.1 ) Income tax expense $ 725,101 (2.0 )% $ 480,206 (0.5 )% The federal and state income tax expense (benefit) for the years ended September 30, 2024 2023 2024 2023 Deferred – U.S. $ — $ (63,426 ) Deferred – U.K. 423,127 262,612 Deferred – Malaysia (55,945 ) (21,687 ) Subtotal 367,182 177,499 Current – U.S. — (8,624 ) Current – Malaysia 357,919 311,331 Subtotal 357,919 302,707 Income tax expense $ 725,101 $ 480,206 Significant components of the Company’s deferred tax assets and liabilities are as follows: 2024 2023 Deferred tax assets: Federal net operating loss carryforwards $ 34,485,560 $ 29,100,871 State net operating loss carryforwards 3,662,406 3,322,715 Foreign net operating loss carryforwards – U.K. 15,303,535 15,749,809 Foreign capital allowance – U.K. 184,779 174,748 Share-based compensation – U.K. 299,868 217,821 U.S. research and development tax credit carryforward 7,647,885 8,303,411 U.S. research and development expense 8,969,277 9,771,166 Accrued compensation 911,277 190,397 Share-based compensation 10,198,368 7,896,221 Interest expense 2,241,652 2,602,890 U.S. credit loss provision 885,562 885,562 Other, net – Malaysia 59,992 4,046 Other, net – U.K. 2,500 2,500 Other, net – U.S. 385,414 71,509 Gross deferred tax assets 85,238,075 78,293,666 Valuation allowance for deferred tax assets (72,502,102 ) (65,135,088 ) Net deferred tax assets 12,735,973 13,158,578 Deferred tax liabilities: Change in fair value of derivative liability (395,736 ) (449,812 ) Covenant not-to-compete — (1,347 ) Net deferred tax liabilities (395,736 ) (451,159 ) Net deferred tax asset $ 12,340,237 $ 12,707,419 The deferred tax amounts have been classified in the accompanying consolidated balance sheets as follows: 2024 2023 Long-term deferred tax asset – U.K. $ 12,280,245 $ 12,703,373 Long-term deferred tax asset – Malaysia 59,992 4,046 Total long-term deferred tax asset $ 12,340,237 $ 12,707,419 ASC Topic 740 740 two not The Company files tax returns in all appropriate jurisdictions, including foreign, U.S. federal and state tax returns. The following summarizes open tax years in the relevant jurisdictions: ● For the U.S., a tax return may 3 3 2005 2007, 2015 2019, 2022 2023, 2025 2038 no ● For Malaysia, a tax return may 5 7 2019 2023, December 31, 2024 2028. ● For the U.K., a tax return may 1 1 2023, 2025. The fiscal 2024 not September 30, 2024 2023 The Company recognizes interest and penalties related to uncertain tax positions as income tax expense as incurred. No September 30, 2024 2023

Note 15 - Sale of ENTADFI Asset

Note 15 - Sale of ENTADFI Assets	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Note 15 Sale of ENTADFI On April 19, 2023, December 2021, April 19, 2023. September 30, 2023, April 19, 2024 “April 2024 September 30, 2024 ( “September 2024 April 2024 On September 29, 2023, September 30, 2023 1 September 29, 2023 2 October 3, 2023 September 29, 2023 October 3, 2023, October 3, 2023 one December 31, 2023. September 5, 2024. September 24, 2024, one forty 1:40 September 24, 2024, On April 24, 2024, April 2024 not April 29, 2024, April 25, 2024, April 2024 April 19, 2024, may may April 24, 2024 March 31, 2025 not ONCO agreed in the Forbearance Agreement to make the following required payments during the Forbearance Period towards the remaining principal balance of the April 2024 1 2 On September 19, 2024, September 2024 Pursuant to the Amended Forbearance Agreement, the forbearance period relating to the Company’s agreement to forbear from exercising its rights and remedies on account of the failure by the Borrower to pay the amounts due under the April 2024 April 19, 2024 March 31, 2025 “April 2024 September June 30, 2025 September 2024 The Borrower agreed in the Amended Forbearance Agreement to make the following required payments (the “Required Payments”) during the April 2024 first April 2024 April 2024 ● monthly payments equal to 25% (increased from 15% in the Original Forbearance Agreement) of cash receipts of the Borrower or its subsidiaries from certain sale or licensing revenues or payments, which increased amount shall begin on October 20, 2024 September 2024; ● payment of 20% (increased from 10% in the Original Forbearance Agreement) of the net proceeds from certain financing or other transactions outside the ordinary course of business completed by the Borrower or any of its subsidiaries during the April 2024 September 19, 2024. The remaining balance of the April 2024 April 2024 The Borrower and the Company also agreed to the following amendments to the September 2024 ● As noted above, an extension of the maturity date to June 30, 2025; ● The accrual of interest at the rate of 10% per annum on any unpaid principal balance of the September 2024 October 1, 2024 September 2024 ● Any amounts owed on the September 2024 not ● Following full repayment of all principal and interest under the April 2024 first September 2024 September 2024 ● If the aggregate unpaid principal outstanding under the April 2024 September 2024 December 31, 2024, September 2024 September 2024 The Company and ONCO entered into a Waiver and Amendment No. 1 November 26, 2024, x The Company received payments of $0.3 million during the year ended September 30, 2024 September 30, 2024 The Company determined that it was not September 30, 2024, 2023. September 30, 2024

Note 16 - Loss Per Share

Note 16 - Loss Per Share	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 16 Loss per Share Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing net income by the weighted average number of common shares outstanding during the period after giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of the incremental common shares issuable upon the exercise of stock options and stock appreciation rights as determined under the treasury stock method. Due to our net loss for the periods presented, all potentially dilutive instruments were excluded because their inclusion would have been anti-dilutive. See Note 11

Note 17 - Employee Benefit Plan

Note 17 - Employee Benefit Plans	12 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Defined Benefit Plan [Text Block]	Note 17 Employee Benefit Plans Effective January 1, 2018, 401 January 1, 2024, 401 September 30, 2023 September 30, 2024. January 1, 2025 In March 2014, January 1, 2019, September 30, 2024 2023

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation and nature of operations 1 FC2 Condom/FC2 FC2 December 2021. April 19, 2023. 15 2024 2023 FC2. FC2
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications no
Use of Estimates, Policy [Policy Text Block]	Use of estimates
Segment Reporting, Policy [Policy Text Block]	Segments
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents and concentration three three
Investment, Policy [Policy Text Block]	Investments in equity securities 825, Financial Instruments September 30, 2024 3
Accounts Receivable and Concentration of Credit Risk [Policy Text Block]	Accounts receivable and concentration of credit risk
Inventory, Policy [Policy Text Block]	Inventories first first not not The Company capitalizes inventory costs associated with its drug products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Prior to an initial regulatory approval for our drug products under clinical development, we expense costs relating to the production of inventory as research and development expense in the Company’s consolidated statements of operations, in the period incurred.
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed assets
Lessee, Leases [Policy Text Block]	Leases not not Operating lease costs are recognized for fixed lease payments on a straight-line basis over the term of the lease. Finance lease costs are a combination of the amortization expense for the ROU asset and interest expense for the outstanding lease liability using the applicable discount rate. Variable lease payments are recognized when incurred based on occurrence or usage. Short-term leases with an initial term of 12 not
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and trademarks
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and intangible assets October 31, 2016. not fourth may not Goodwill consists of the cost of an acquired business in excess of the fair value of the net assets acquired. The Company’s goodwill is assigned to the reporting unit that is expected to benefit from the synergies of a business combination. The Company has identified two single first not not may Regarding goodwill, the estimated fair value of a reporting unit is highly sensitive to changes in projections and assumptions; therefore, in some instances changes in these assumptions could potentially lead to impairment. We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing. Changes in these assumptions may not may Intangible assets are highly vulnerable to impairment charges, particularly IPR&D. These assets are initially measured at fair value and therefore any reduction in expectations used in the valuations could potentially lead to impairment. Some of the more common potential risks leading to impairment include competition, earlier than expected loss of exclusivity, pricing pressures, adverse regulatory changes or clinical trial results, delay or failure to obtain regulatory approval, additional development costs, inability to achieve expected synergies, higher operating costs, changes in tax laws and other macro-economic changes. The complexity in estimating the fair value of intangible assets in connection with an impairment test is similar to the initial valuation. During fiscal 2023, 8 September 30, 2024 2023,
Deferred Charges, Policy [Policy Text Block]	Deferred financing costs 10 September 30, 2024 2023
Fair Value Measurement, Policy [Policy Text Block]	Fair value measurements 820 Fair Value Measurements and Disclosures, 820 not not 3 The carrying amounts reported in the accompanying consolidated balance sheets for cash, accounts receivable, accounts payable and other accrued liabilities approximate their fair value based on the short-term nature of these instruments. The carrying value of the residual royalty agreement liabilities, taking into consideration the related derivative instruments, is estimated to approximate fair value.
Derivatives, Policy [Policy Text Block]	Derivative instruments not not 9.
Revenue [Policy Text Block]	Revenue recognition 4
Research and Development Expense, Policy [Policy Text Block]	Research and development costs no no not September 30, 2024 2023 The Company records estimated costs of research and development activities conducted by third third not may
Share-Based Payment Arrangement [Policy Text Block]	Share-based compensation
Advertising Cost [Policy Text Block]	Advertising September 30, 2024 2023
Income Tax, Policy [Policy Text Block]	Income taxes 740 not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation and operations October 1, 2009, September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023
Comprehensive Income, Policy [Policy Text Block]	Other comprehensive loss The U.S. parent company and its U.K. subsidiary routinely purchase inventory produced by its Malaysia subsidiary for sale to their respective customers. These intercompany trade accounts are eliminated in consolidation. The Company’s policy and intent is to settle the intercompany trade account on a current basis. Since the U.K. and Malaysia subsidiaries adopted the U.S. dollar as their functional currencies effective October 1, 2009, 2024 2023
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements not November 2023, 2023 07, Segment Reporting (Topic 280 2023 07 2023 07 10 September 30, 2025, 2023 07 In December 2023, 2023 09, Income Taxes (Topic 740 2023 09 September 30, 2026, 2023 09 In November 2024, 2024 03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220 40 2024 03 September 30, 2028, 2024 03 We have reviewed all other recently issued accounting pronouncements and have determined that such standards that are not not not

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2024
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	2024 2023 Beginning balance $ 1,331,000 $ 4,294,000 Change in fair value of derivative liabilities 239,000 (2,963,000 ) Ending balance $ 1,570,000 $ 1,331,000
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Valuation Methodology Significant Unobservable Input 2024 2023 Scenario-Based Estimated change of control dates March 2025 to March 2027 December 2024 to December 2026 Discount rate 12.1% to 12.3% 14.1% to 15.1% Probability of change of control 60% to 90% 20% to 90%

Note 4 - Revenue from Contrac_2

Note 4 - Revenue from Contracts with Customers (Tables)	12 Months Ended
	Sep. 30, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	2024 2023 FC2 Global public health sector $ 14,485,159 $ 10,460,024 U.S. prescription channel 2,401,260 5,823,921 Total FC2 16,886,419 16,283,945 Other — 13,013 Net revenues $ 16,886,419 $ 16,296,958
Revenue from External Customers by Geographic Areas [Table Text Block]	2024 2023 United States $ 5,354,090 $ 8,370,202 South Africa 1,902,149 1,941,678 Brazil 2,760,540 * Mozambique 2,172,840 * Other 4,696,800 5,985,078 Net revenues $ 16,886,419 $ 16,296,958

Note 5 - Accounts Receivable _2

Note 5 - Accounts Receivable and Concentration of Credit Risk (Tables)	12 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	2024 2023 Trade receivables, gross $ 7,897,739 $ 8,445,370 Less: allowance for credit losses (3,923,857 ) (3,923,857 ) Less: allowance for sales returns and payment term discounts (13,577 ) (15,005 ) Accounts receivable, net $ 3,960,305 $ 4,506,508
Accounts Receivable, Allowance for Credit Loss [Table Text Block]	2024 2023 Beginning balance $ 3,923,857 $ 12,143 Charge-offs, net of recoveries — 3,911,714 Ending balance $ 3,923,857 $ 3,923,857

Note 6 - Inventories (Tables)

Note 6 - Inventories (Tables)	12 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	2024 2023 Raw material $ 827,582 $ 1,854,810 Work in process 79,181 112,799 Finished goods 4,819,331 4,913,295 Inventories, gross 5,726,094 6,880,904 Less: inventory reserves (1,581,915 ) (183,787 ) Inventories, net $ 4,144,179 $ 6,697,117

Note 7 - Property and Equipme_2

Note 7 - Property and Equipment (Tables)	12 Months Ended
	Sep. 30, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	Estimated Useful Life (years) 2024 2023 Property and equipment: Manufacturing equipment 5 - 8 $ 2,863,792 $ 3,008,122 Office equipment, furniture and fixtures 3 - 10 1,479,193 1,471,870 Leasehold improvements 3 - 8 960,694 960,694 Total property and equipment 5,303,679 5,440,686 Less: accumulated depreciation and amortization (4,019,025 ) (3,787,954 ) Property and equipment, net $ 1,284,654 $ 1,652,732

Note 8 - Intangible Assets an_2

Note 8 - Intangible Assets and Goodwill (Tables)	12 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	Gross Carrying Accumulated Net Book Amount Amortization Value Intangible asset with finite life: Covenants not-to-compete $ 500,000 $ 494,048 $ 5,952 Indefinite-lived intangible assets: Acquired in-process research and development assets — — — Total intangible assets $ 500,000 $ 494,048 $ 5,952

Note 9 - Debt (Tables)

Note 9 - Debt (Tables)	12 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Debt [Table Text Block]	2024 2023 Residual royalty agreement liability, fair value at inception $ 346,000 $ 346,000 Add: accretion of liability using effective interest rate 12,985,419 12,377,949 Less: cumulative payments (5,024,790 ) (4,320,190 ) Residual royalty agreement liability, excluding embedded derivative liability 8,306,629 8,403,759 Add: embedded derivative liability at fair value (see Note 3) 1,570,000 1,331,000 Total residual royalty agreement liability 9,876,629 9,734,759 Residual royalty agreement liability, short-term portion (1,025,837 ) (864,623 ) Residual royalty agreement liability, long-term portion $ 8,850,792 $ 8,870,136

Note 11 - Share-based Compens_2

Note 11 - Share-based Compensation (Tables)	12 Months Ended
	Sep. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	2024 2023 Cost of sales $ 404,348 $ 361,843 Selling, general and administrative 10,379,520 13,785,067 Research and development 2,860,537 3,771,693 $ 13,644,405 $ 17,918,603
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2024 2023 Weighted Average Assumptions: Expected Volatility 108.97 % 101.37 % Expected Dividend Yield 0.00 % 0.00 % Risk-free Interest Rate 4.44 % 3.92 % Expected Term (in years) 6.0 6.0 Fair Value of Options Granted $ 1.18 $ 5.55
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Remaining Aggregate Number of Exercise Price Contractual Term Intrinsic Shares Per Share (years) Value Outstanding at September 30, 2023 17,367,643 $ 5.28 Granted 2,467,980 1.40 Exercised (2,734 ) 1.20 Forfeited (1,370,461 ) 7.56 Outstanding at September 30, 2024 18,462,428 $ 4.59 6.32 $ 44,938 Exercisable at September 30, 2024 12,740,284 $ 4.42 5.27 $ —

Note 12 - Leases (Tables)

Note 12 - Leases (Tables)	12 Months Ended
	Sep. 30, 2024
Notes Tables
Lease, Cost [Table Text Block]	2024 2023 Operating lease cost $ 1,078,058 $ 1,117,463 Short-term lease cost 42,683 42,809 Variable lease cost 79,066 186,904 Sublease income (15,148 ) (179,378 ) Total lease cost $ 1,184,659 $ 1,167,798
Lessee, Operating Lease [Table Text Block]	2024 2023 Operating Leases Weighted-average remaining lease term 5.0 6.1 Weighted-average discount rate 7.5 % 7.7 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Operating Leases Fiscal year ended September 30, 2025 $ 1,110,198 2026 801,893 2027 814,728 2028 833,137 2029 856,526 Thereafter 361,270 Total lease payments 4,777,752 Less imputed interest (790,875 ) Total lease liabilities $ 3,986,877

Note 14 - Income Taxes (Tables)

Note 14 - Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	2024 2023 Domestic $ (37,791,920 ) $ (90,522,387 ) Foreign 715,595 (2,150,099 ) Total $ (37,076,325 ) $ (92,672,486 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2024 2023 Amount Tax Rate Amount Tax Rate Income tax benefit at U.S. federal statutory rates $ (7,786,028 ) 21.0 % $ (19,461,222 ) 21.0 % State income tax benefit, net of federal benefits (602,861 ) 1.6 (1,506,855 ) 1.6 Non-deductible expenses 200,233 (0.5 ) 330,281 (0.3 ) U.S. research and development tax credit 655,526 (1.8 ) 178,378 (0.2 ) Effect of foreign income tax rates 292,970 (0.8 ) 454,808 (0.5 ) Effect of common stock options exercised 13,339 0.0 180,847 (0.2 ) Effect of global intangible low-taxed income 500,613 (1.4 ) (24,691 ) (0.0 ) Change in valuation allowance 7,367,014 (19.9 ) 20,205,808 (21.8 ) Other, net 84,295 (0.2 ) 122,852 (0.1 ) Income tax expense $ 725,101 (2.0 )% $ 480,206 (0.5 )%
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2024 2023 Deferred – U.S. $ — $ (63,426 ) Deferred – U.K. 423,127 262,612 Deferred – Malaysia (55,945 ) (21,687 ) Subtotal 367,182 177,499 Current – U.S. — (8,624 ) Current – Malaysia 357,919 311,331 Subtotal 357,919 302,707 Income tax expense $ 725,101 $ 480,206
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2024 2023 Deferred tax assets: Federal net operating loss carryforwards $ 34,485,560 $ 29,100,871 State net operating loss carryforwards 3,662,406 3,322,715 Foreign net operating loss carryforwards – U.K. 15,303,535 15,749,809 Foreign capital allowance – U.K. 184,779 174,748 Share-based compensation – U.K. 299,868 217,821 U.S. research and development tax credit carryforward 7,647,885 8,303,411 U.S. research and development expense 8,969,277 9,771,166 Accrued compensation 911,277 190,397 Share-based compensation 10,198,368 7,896,221 Interest expense 2,241,652 2,602,890 U.S. credit loss provision 885,562 885,562 Other, net – Malaysia 59,992 4,046 Other, net – U.K. 2,500 2,500 Other, net – U.S. 385,414 71,509 Gross deferred tax assets 85,238,075 78,293,666 Valuation allowance for deferred tax assets (72,502,102 ) (65,135,088 ) Net deferred tax assets 12,735,973 13,158,578 Deferred tax liabilities: Change in fair value of derivative liability (395,736 ) (449,812 ) Covenant not-to-compete — (1,347 ) Net deferred tax liabilities (395,736 ) (451,159 ) Net deferred tax asset $ 12,340,237 $ 12,707,419
Schedule of Deferred Tax Balance Sheet Classification [Table Text Block]	2024 2023 Long-term deferred tax asset – U.K. $ 12,280,245 $ 12,703,373 Long-term deferred tax asset – Malaysia 59,992 4,046 Total long-term deferred tax asset $ 12,340,237 $ 12,707,419

Note 1 - Nature of Business a_2

Note 1 - Nature of Business and Significant Accounting Policies (Details Textual)		3 Months Ended	12 Months Ended
	Oct. 01, 2009 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Sep. 24, 2024 shares
Number of Reporting Units			2
Number of Operating Segments			1
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)			$ 0	$ 3,900,000
Advertising Expense			800,000	900,000
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax			600,000	600,000
Assets			60,418,772	50,023,091
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$ 0
Non-US [Member]
Assets			9,200,000	10,500,000
In Process Research and Development [Member]
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)		$ 3,900,000	$ 3,900,000	$ 3,900,000
Common Stock [Member]
Investment Owned, Balance, Shares (in shares) | shares			142,749		142,749
Investment Owned, Balance, Principal Amount			$ 700,000
FC2 Female Condom [Member] | Private Commercial and Public Healthcare Sector [Member]
Number of Countries in which Entity Operates			150	150

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements (Details Textual)	1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Oct. 03, 2024 yr	Sep. 24, 2024 shares	Jun. 30, 2024 shares	Oct. 03, 2023 USD ($)
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)			$ 0	$ 3,900,000
Equity Securities, FV-NI, Unrealized Gain (Loss)			$ (176,077)	0
Fair Value, Inputs, Level 3 [Member] | BWV Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Equity Securities, FV-NI, Measurement Input					0.79
Fair Value, Inputs, Level 3 [Member] | BWV Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Equity Securities, FV-NI, Measurement Input | yr					3
Fair Value, Inputs, Level 3 [Member] | BWV Preferred Stock [Member] | Measurement Input, Discount Rate [Member]
Equity Securities, FV-NI, Measurement Input					0.35
Fair Value, Inputs, Level 3 [Member] | BWV Preferred Stock [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Equity Securities, FV-NI, Measurement Input					0.15
Fair Value, Inputs, Level 3 [Member] | BWV Preferred Stock [Member] | Measurement Input, Probability Of Dissolution [Member[
Equity Securities, FV-NI, Measurement Input					0.60
Common Stock [Member]
Investment Owned, Balance, Shares (in shares) | shares			142,749			142,749
Investment Owned, Balance, Principal Amount			$ 700,000
Equity Securities, FV-NI, Unrealized Gain (Loss)			(200,000)
Common Stock [Member] | Subsequent Event [Member]
Proceeds from Sale of Equity Securities, FV-NI	$ 400,000
Series A Convertible Preferred Stock [Member]
Investment Owned, Balance, Shares (in shares) | shares							3,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value								$ 900,000
In Process Research and Development [Member]
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)		$ 3,900,000	$ 3,900,000	$ 3,900,000

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurements - Schedule of Reconciliation of Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Inputs, Level 3 [Member] - Embedded Derivative Financial Instruments [Member] - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Balance	$ 1,331,000	$ 4,294,000
Change in fair value of derivative liabilities	239,000	(2,963,000)
Balance	$ 1,570,000	$ 1,331,000

Note 3 - Fair Value Measureme_5

Note 3 - Fair Value Measurements - Schedule of Valuation Approach and Technique (Details) - Fair Value, Inputs, Level 3 [Member] - Embedded Derivative Financial Instruments [Member] - Valuation, Scenario-based [Member]	Sep. 30, 2024	Sep. 30, 2023
Minimum [Member] | Measurement Input, Discount Rate [Member]
Measurement input	0.121	0.141
Minimum [Member] | Measurement Input, Probability of Change of Control [Member]
Measurement input	0.60	0.20
Maximum [Member] | Measurement Input, Discount Rate [Member]
Measurement input	0.123	0.151
Maximum [Member] | Measurement Input, Probability of Change of Control [Member]
Measurement input	0.90	0.90

Note 4 - Revenue from Contrac_3

Note 4 - Revenue from Contracts with Customers (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Oct. 01, 2022
Contract with Customer, Liability, Current	$ 0.4	$ 0.1	$ 0.3
Contract with Customer, Liability, Revenue Recognized	$ 0.1	$ 0.3

Note 4 - Revenue from Contrac_4

Note 4 - Revenue from Contracts with Customers - Schedule of Revenue by Products (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Net revenues	$ 16,886,419	$ 16,296,958
FC2 Female Condom [Member]
Net revenues	16,886,419	16,283,945
FC2 Female Condom [Member] | Sales Channel, U.S. Prescription Channel [Member]
Net revenues	2,401,260	5,823,921
FC2 Female Condom [Member] | Global Public Healthcare Sector [Member]
Net revenues	14,485,159	10,460,024
Product and Service, Other [Member]
Net revenues	$ 0	$ 13,013

Note 4 - Revenue from Contrac_5

Note 4 - Revenue from Contracts with Customers - Schedule of Revenue by Geographical Area (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Net revenues	$ 16,886,419	$ 16,296,958
UNITED STATES
Net revenues	5,354,090	8,370,202
SOUTH AFRICA
Net revenues	1,902,149	1,941,678
BRAZIL
Net revenues	2,760,540
MOZAMBIQUE
Net revenues	2,172,840
Other Geographical Areas [Member]
Net revenues	$ 4,696,800	$ 5,985,078

Note 5 - Accounts Receivable _3

Note 5 - Accounts Receivable and Concentration of Credit Risk (Details Textual) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023 USD ($)	Oct. 01, 2022 USD ($)
Accounts Receivable, after Allowance for Credit Loss			$ 3.6
The Pill Club [Member] | Unlikely to be Collected Financing Receivable [Member]
Accounts Receivable, Allowance for Credit Loss		$ 3.9
Customer Concentration Risk [Member] | Accounts Receivable Current, In Relation To Current Assets [Member]
Number of Customers	0	0
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Customers	2	3
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage	64%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage		71%
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Customers	4	2
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Customers [Member]
Concentration Risk, Percentage		47%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Four Customers [Member]
Concentration Risk, Percentage	60%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | The Pill Club [Member]
Concentration Risk, Percentage		24%

Note 5 - Accounts Receivable _4

Note 5 - Accounts Receivable and Concentration of Credit Risk - Schedule of Accounts Receivable (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Trade receivables, gross	$ 7,897,739	$ 8,445,370
Less: allowance for credit losses	(3,923,857)	(3,923,857)	$ (12,143)
Less: allowance for sales returns and payment term discounts	(13,577)	(15,005)
Accounts receivable, net	$ 3,960,305	$ 4,506,508

Note 5 - Accounts Receivable _5

Note 5 - Accounts Receivable and Concentration of Credit Risk - Schedule of Allowance for Credit Losses (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Balance	$ 3,923,857	$ 12,143
Charge-offs, net of recoveries	0	3,911,714
Balance	$ 3,923,857	$ 3,923,857

Note 6 - Inventories (Details T

Note 6 - Inventories (Details Textual) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Inventory Valuation Reserves	$ 1,581,915	$ 183,787

Note 6 - Inventories - Schedule

Note 6 - Inventories - Schedule of Inventories (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Raw material	$ 827,582	$ 1,854,810
Work in process	79,181	112,799
Finished goods	4,819,331	4,913,295
Inventories, gross	5,726,094	6,880,904
Less: inventory reserves	(1,581,915)	(183,787)
Inventories, net	$ 4,144,179	$ 6,697,117

Note 7 - Property and Equipme_3

Note 7 - Property and Equipment (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Depreciation	$ 0.3	$ 0.2
Equipment, Furniture, and Leasehold Improvements [Member]
Deposit Assets		$ 0.2

Note 7 - Property and Equipme_4

Note 7 - Property and Equipment - Schedule of Plant and Equipment (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Plant and equipment	$ 5,303,679	$ 5,440,686
Less: accumulated depreciation and amortization	(4,019,025)	(3,787,954)
Property and equipment, net	1,284,654	1,652,732
Equipment [Member]
Plant and equipment	$ 2,863,792	3,008,122
Equipment [Member] | Minimum [Member]
Plant and equipment, useful life (Year)	5 years
Equipment [Member] | Maximum [Member]
Plant and equipment, useful life (Year)	8 years
Office Equipment, Furniture and Fixtures [Member]
Plant and equipment	$ 1,479,193	1,471,870
Office Equipment, Furniture and Fixtures [Member] | Minimum [Member]
Plant and equipment, useful life (Year)	3 years
Office Equipment, Furniture and Fixtures [Member] | Maximum [Member]
Plant and equipment, useful life (Year)	10 years
Leasehold Improvements [Member]
Plant and equipment	$ 960,694	$ 960,694
Leasehold Improvements [Member] | Minimum [Member]
Plant and equipment, useful life (Year)	3 years
Leasehold Improvements [Member] | Maximum [Member]
Plant and equipment, useful life (Year)	8 years

Note 8 - Intangible Assets an_3

Note 8 - Intangible Assets and Goodwill (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)		$ 0	$ 3,900,000
Goodwill		6,878,932	6,878,932
Goodwill, Period Increase (Decrease)		0	0
In Process Research and Development [Member]
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)	$ 3,900,000	$ 3,900,000	3,900,000
Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		7 years
Amortization of Intangible Assets			$ 71,000

Note 8 - Intangible Assets an_4

Note 8 - Intangible Assets and Goodwill - Schedule of Intangible Assets (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Accumulated Amortization		$ 494,048
Total intangible assets		500,000
Total intangible assets, net	$ 0	5,952
In Process Research and Development [Member]
Indefinite-lived intangible assets net		0
Indefinite-lived intangible assets, net		0
Noncompete Agreements [Member]
Finite-lived intangible asset		500,000
Accumulated Amortization		494,048
Finite-lived intangible asset, net		$ 5,952

Note 9 - Debt (Details Textual)

Note 9 - Debt (Details Textual) - USD ($) $ in Thousands		12 Months Ended
	Mar. 05, 2018	Sep. 30, 2024	Sep. 30, 2023	Nov. 01, 2022
Credit Agreement [Member]
Debt Instrument, Face Amount	$ 10,000
Long-Term Debt	$ 0
Residual Royalty Financing Agreement [Member]
Royalty Agreement, Payment, Percentage	5%
Residual Royalty Financing Agreement [Member] | Scenario, Change of Control or Sale of Business [Member]
Royalty Agreement, Payment, Percentage	5%
Royalty Agreement, Payment to Agent	$ 2,000
Credit Agreement and Residual Royalty Financing Agreement [Member]
Debt Instrument, Face Amount	$ 10,000
Debt Instrument, Repaid, Principal		$ 10,000
Premium Finance Agreement [Member]
Debt Instrument, Face Amount				$ 1,400
Debt Instrument, Interest Rate, Stated Percentage				6.30%
Accrued Liabilities and Other Liabilities		$ 0	$ 100

Note 9 - Debt - Schedule of Res

Note 9 - Debt - Schedule of Residual Royalty Agreement Liability (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Residual royalty agreement liability, fair value at inception	$ 346,000	$ 346,000
Add: accretion of liability using effective interest rate	12,985,419	12,377,949
Less: cumulative payments	(5,024,790)	(4,320,190)
Residual royalty agreement liability, excluding embedded derivative liability	8,306,629	8,403,759
Add: embedded derivative liability at fair value (see Note 3)	1,570,000	1,331,000
Total residual royalty agreement liability	9,876,629	9,734,759
Residual royalty agreement liability, short-term portion	(1,025,837)	(864,623)
Residual royalty agreement, long-term portion (Note 9)	$ 8,850,792	$ 8,870,136

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Details Textual) - USD ($)							12 Months Ended		36 Months Ended
	Dec. 18, 2023	Dec. 13, 2023	May 12, 2023	May 02, 2023	Apr. 12, 2023	Jun. 26, 2020	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2023	Mar. 31, 2023
Preferred Stock, Shares Issued (in shares)							0	0	0
Preferred Stock, Shares Outstanding (in shares)							0	0	0
Common Stock, Shares Authorized (in shares)							308,000,000	308,000,000	308,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.01	$ 0.01	$ 0.01
Security Offering, Maximum Value of Securities, Shelf Registration										$ 200,000,000
Security Offering, Remaining Value of Securities, Shelf Registration							$ 109,000,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs							164,313	$ 138,182
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	52,708,332
Shares Issued, Price Per Share (in dollars per share)	$ 0.72
Proceeds from Issuance or Sale of Equity	$ 35,200,000						35,228,564	$ 0
Stock Issued During Period, Value, New Issues							35,228,564
Aspire Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)								2,779,713	4,424,450
Share Purchase Agreement, Term (Month)						36 months			36 months
Shares Purchase Agreement, Value, Shares Authorized						$ 23,900,000
Stock Issued During Period, Value, New Issues								$ 3,400,000	$ 8,400,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs								$ 105,000
Stock Issued During Period, Shares, Issued for Services (in shares)								212,130
Stock Issued During Period, Value, Issued for Services								$ 700,000
Deferred Offering Costs								700,000	700,000
Unamortized Debt Issuance Expense								500,000	500,000
Frost Gamma Investments Trust Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)					5,000,000
Shares Issued, Price Per Share (in dollars per share)					$ 1
Proceeds from Issuance or Sale of Equity							0	4,969,045
Stock Issued During Period, Value, New Issues					$ 5,000,000			4,969,045
Proceeds from Issuance of Common Stock					$ 31,000
Lincoln Park Purchase Agreement [Member]
Share Purchase Agreement, Term (Month)				36 months
Stock Issued During Period, Value, New Issues								$ 1,008,000
Stock Issued During Period, Shares, Issued for Services (in shares)								800,000
Stock Issued During Period, Value, Issued for Services							1,000,000
Deferred Offering Costs							57,000
Shares Purchase Agreement, Shares Authorized (in shares)				225,000
Shares Purchase Agreement, Value, Maximum Commitment				$ 2,500,000
Shares Purchase Agreement, Shares, Maximum Commitment (in shares)				2,000,000
Shares Purchase Agreement, Accelerated Purchase Date, Percent Of Trading Volume				30%
Shares Purchase Agreement, Accelerated Purchase Date, Purchase Price, Percent				97%
Shares Purchase Agreement, Shares Authorized, Aggregate Maximum (in shares)				17,678,502
Shares Purchase Agreement, Shares Authorized, Percentage of Common Shares Oustanding				19.99%
Deferred Costs							$ 1,100,000
Shares Purchase Agreement, Value, Aggregate Maximum				$ 50,000,000
Lincoln Park Purchase Agreement [Member] | Shares Required to be Purchased if Closing Price is $6.00 or Above [Member]
Shares Issued, Price Per Share (in dollars per share)				$ 6
Shares Purchase Agreement, Shares Authorized (in shares)				250,000
Lincoln Park Purchase Agreement [Member] | Shares Required to be Purchased if Closing Price is $8.00 or Above [Member]
Shares Issued, Price Per Share (in dollars per share)				$ 8
Shares Purchase Agreement, Shares Authorized (in shares)				275,000
Lincoln Park Purchase Agreement [Member] | Obligation to Issue Shares Based on Aggregation of Stock Ownership [Member]
Stock Issued During Period, Value, New Issues				$ 1,000,000
Lincoln Park Purchase Agreement [Member] | Maximum [Member]
Shares Purchase Agreement, Value, Shares Authorized		$ 50,000,000		$ 100,000,000
Lincoln Park Purchase Agreement [Member] | Weighted Average [Member]
Shares Issued, Price Per Share (in dollars per share)							$ 1.26
Lincoln Park Purchase Agreement 2 [Member]
Stock Issued During Period, Shares, New Issues (in shares)							1,800,000	1,225,000
Stock Issued During Period, Value, New Issues							$ 1,700,000	$ 1,400,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs							200,000	30,000
Unamortized Debt Issuance Expense							$ 900,000	$ 1,000,000	$ 1,000,000
Jefferies Sales Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)							90,156	1,277,259
Proceeds from Issuance or Sale of Equity							$ 66,551	$ 1,040,321
Shares Purchase Agreement, Value, Shares Authorized			$ 75,000,000
Stock Issued During Period, Value, New Issues							66,551	$ 1,040,321
Unamortized Debt Issuance Expense							200,000
Common Stock, Capital Shares Reserved for Future Issuance (in shares)			39,609,072
Loss on Contract Termination							$ 200,000
Preferred Class A [Member]
Preferred Stock, Shares Authorized (in shares)							5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.01
Preferred Stock, Shares Issued (in shares)							0	0	0
Preferred Stock, Shares Outstanding (in shares)							0	0	0
Preferred Class, Series A-1 [Member]
Preferred Stock, Shares Authorized (in shares)							1,040,000
Preferred Class, Series A-2 [Member]
Preferred Stock, Shares Authorized (in shares)							1,500,000
Preferred Class, Series A-3 [Member]
Preferred Stock, Shares Authorized (in shares)							700,000
Preferred Class, Series A-4 [Member]
Preferred Stock, Shares Authorized (in shares)							548,000
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)							15,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.5
Preferred Stock, Shares Issued (in shares)							0	0	0
Preferred Stock, Shares Outstanding (in shares)							0	0	0

Note 11 - Share-based Compens_3

Note 11 - Share-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2017	Jun. 30, 2022	Mar. 31, 2018	Jul. 31, 2017
Share-Based Payment Arrangement, Expense, Tax Benefit	$ 3,100,000	$ 4,000,000
Share-Based Payment Arrangement, Expense	$ 13,644,405	17,918,603
Share Price (in dollars per share)	$ 0.77
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value		500,000
Proceeds from Stock Options Exercised	$ 3,280	389,058
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Share-Based Payment Arrangement, Expense	$ 1,900,000	$ 1,900,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 11,700,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 7 months 6 days
Stock Appreciation Rights (SARs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)			10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 0.95
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)	50,000	50,000
Stock Appreciation Rights (SARs) [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
Stock Appreciation Rights (SARs) [Member] | Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			50,000
The 2022 Employment Inducement Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	3,967,083			4,000,000
The 2018 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	1,817,159
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)					18,500,000
The 2017 Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	11,085
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)						4,700,000
The 2008 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)						0

Note 11 - Share-based Compens_4

Note 11 - Share-based Compensation - Schedule of Allocated Expense (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
share-based compensation expenses	$ 13,644,405	$ 17,918,603
Cost of Sales [Member]
share-based compensation expenses	404,348	361,843
Selling, General and Administrative Expenses [Member]
share-based compensation expenses	10,379,520	13,785,067
Research and Development Expense [Member]
share-based compensation expenses	$ 2,860,537	$ 3,771,693

Note 11 - Share-based Compens_5

Note 11 - Share-based Compensation of Assumptions (Details) - $ / shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Expected Volatility	108.97%	101.37%
Expected Dividend Yield	0%	0%
Risk-free Interest Rate	4.44%	3.92%
Expected Term (in years) (Year)	6 years	6 years
Fair Value of Options Granted (in dollars per share)	$ 1.18	$ 5.55

Note 11 - Share-based Compens_6

Note 11 - Share-based Compensation - Schedule of Options (Details)	12 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Outstanding, balance (in shares) | shares	17,367,643
Outstanding, exercise price (in dollars per share) | $ / shares	$ 5.28
Granted (in shares) | shares	2,467,980
Granted, exercise price (in dollars per share) | $ / shares	$ 1.4
Exercised (in shares) | shares	(2,734)
Exercised, exercise price (in dollars per share) | $ / shares	$ 1.2
Forfeited (in shares) | shares	(1,370,461)
Forfeited, exercise price (in dollars per share) | $ / shares	$ 7.56
Outstanding, balance (in shares) | shares	18,462,428
Outstanding, exercise price (in dollars per share) | $ / shares	$ 4.59
Outstanding, remaining contractual term (Year)	6 years 3 months 25 days
Outstanding, intrinsic value | $	$ 44,938
Exercisable (in shares) | shares	12,740,284
Exercisable, exercise price (in dollars per share) | $ / shares	$ 4.42
Exercisable, remaining contractual term (Year)	5 years 3 months 7 days
Exercisable, intrinsic value | $	$ 0

Note 12 - Leases (Details Textu

Note 12 - Leases (Details Textual)						12 Months Ended
	Mar. 01, 2022 USD ($) ft²	Aug. 01, 2020 USD ($) ft²	Sep. 01, 2019 USD ($) ft²	Jan. 01, 2018 USD ($)	Nov. 01, 2016 USD ($) ft²	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Increase (Decrease) in Operating Lease Liability						$ (683,827)	$ (666,863)
Operating Lease, Payments						$ 1,000,000	900,000
Lessee, Operating Lease, Discount Rate						0%
Lease, Corporate Headquarters in Miami, Florida [Member]
Area of Real Estate Property (Square Foot) | ft²	12,000
Lessee, Operating Lease, Term of Contract (Year)	8 years
Lessee, Operating Lease, Annual Base Rent, Per Square Foot	$ 58
Lessee, Operating Lease, Annual Base Rent, Percentage Increase	3%
Security Deposit						$ 117,000	$ 117,000
Lease, Office Space in Chicago, Illinois [Member]
Area of Real Estate Property (Square Foot) | ft²					6,600
Lessee, Operating Lease, Term of Contract (Year)					7 years
Lessee, Operating Lease, Annual Base Rent, Per Square Foot					$ 14
Lessee, Operating Lease, Holiday Term (Month)					7 months
Lessee, Operating Lease, Abatement Term (Year)					5 years
Lessee, Operating Sublease, Monthly Income				$ 15,200
Security Deposit Liability				30,000
Lease, Office Space in Chicago, Illinois [Member] | Maximum [Member]
Lessee, Operating Lease, Annual Base Rent, Per Square Foot					$ 17
Lessee, Operating Sublease, Monthly Income				$ 17,300
Lease, Office Space in London England [Member]
Area of Real Estate Property (Square Foot) | ft²		6,400
Lessee, Operating Lease, Term of Contract (Year)		5 years
Security Deposit		$ 58,000			$ 55,000
Lessee, Operating Lease, Option to Terminate, Term (Year)		3 years
Lessee, Operating Lease, Option to Terminate, Notification Term (Month)		6 months
Increase (Decrease) in Operating Lease Liability		$ 265,000
Lessee, Operating Lease, Quarterly Rental Payments		41,100
Increase (Decrease) in Operating Lease, Right-of-use Asset		$ 265,000
Lease, Manufacturing and Warehouse Space in Selangor D.E., Malaysia [Member]
Area of Real Estate Property (Square Foot) | ft²			45,800
Lessee, Operating Lease, Term of Contract (Year)			3 years
Security Deposit			$ 46,000
Lessee, Operating Lease, Option to Terminate, Term (Year)			3 years
Lessee, Operating Lease, Monthly Rental Payments			$ 15,400

Note 12 - Leases - Schedule of

Note 12 - Leases - Schedule of Lease Cost (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating lease cost	$ 1,078,058	$ 1,117,463
Short-term lease cost	42,683	42,809
Variable lease cost	79,066	186,904
Sublease income	(15,148)	(179,378)
Total lease cost	$ 1,184,659	$ 1,167,798

Note 12 - Leases - Schedule o_2

Note 12 - Leases - Schedule of Operating Leases (Details)	Sep. 30, 2024	Sep. 30, 2023
Weighted-average remaining lease term (Year)	5 years	6 years 1 month 6 days
Weighted-average discount rate	7.50%	7.70%

Note 12 - Leases - Schedule o_3

Note 12 - Leases - Schedule of Operating Leases Maturity (Details)	Sep. 30, 2024 USD ($)
2025	$ 1,110,198
2026	801,893
2027	814,728
2028	833,137
2029	856,526
Thereafter	361,270
Total lease payments	4,777,752
Less imputed interest	(790,875)
Total lease liabilities	$ 3,986,877

Note 13 - Contingent Liabilit_2

Note 13 - Contingent Liabilities (Details Textual) - USD ($)		12 Months Ended
	Feb. 29, 2024	Sep. 30, 2024	Sep. 30, 2023
Research and Development Expense		$ 12,808,185	$ 51,202,219
Accounts Payable, Current		3,036,841	12,931,172
Other Liabilities, Noncurrent		4,461,920	$ 29,948
Damages from Product Defects [Member]
Product Liability Contingency, Loss Exposure Not Accrued, Best Estimate		10,000,000
Loss Contingency, License and Purchase Agreements [Member]
Loss Contingency Accrual		0
Loss Contingency, Commercial Dispute [Member]
Research and Development Expense		600,000
Loss Contingency, Commercial Dispute [Member] | Research and Development Liability [Member]
Accounts Payable, Current		900,000
Other Liabilities, Noncurrent		$ 4,500,000
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member]
Loss Contingency, Damages Sought, Value	$ 10,000,000
Loss Contingency Accrual, Product Liability, Net	8,300,000
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Due Upon Execution of Agreement [Member]
Loss Contingency Accrual, Product Liability, Net	2,300,000
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Monthly Installments,One [Member]
Loss Contingency Accrual, Product Liability, Net	$ 3,500,000
Product Liability Contingency, Disbursement Period, Estimate, Accrued (Month)	48 months
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Balance by December 31, 2025 [Member]
Loss Contingency Accrual, Product Liability, Net	$ 2,500,000
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Monthly Installments, Two [Member]
Product Liability Contingency, Disbursement Period, Estimate, Accrued (Month)	24 months

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Deferred Tax Assets, Valuation Allowance	$ 72,502,102	$ 65,135,088
Unrecognized Tax Benefits		0	$ 0
Domestic Tax Jurisdiction [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	7,300,000
Deferred Tax Assets, Valuation Allowance	69,000,000	61,700,000
Operating Loss Carryforwards	$ 164,200,000
Open Tax Year	2005 2006 2007 2015 2016 2017 2018 2019 2022 2023
Domestic Tax Jurisdiction [Member] | Tax Year, 2024 to 2043 Expirations [Member]
Operating Loss Carryforwards	$ 28,600,000
Domestic Tax Jurisdiction [Member] | Tax Year, Not Subject to Expiration [Member]
Operating Loss Carryforwards	135,600,000
Domestic Tax Jurisdiction [Member] | Tax Year, 2038 to 2043 Expirations [Member]
Tax Credit Carryforward, Amount	$ 7,600,000
Foreign Tax Jurisdiction [Member] | MALAYSIA
Open Tax Year	2019 2020 2021 2022 2023
Foreign Tax Jurisdiction [Member] | UNITED KINGDOM
Open Tax Year	2023
Foreign Tax Jurisdiction [Member] | Tax Year, Not Subject to Expiration [Member]
Operating Loss Carryforwards	$ 61,200,000
Foreign Tax Jurisdiction [Member] | Female Health Company (UK) plc [Member]
Deferred Tax Assets, Valuation Allowance	0	0
Foreign Tax Jurisdiction [Member] | Veru Biopharma UK Limited [Member]
Deferred Tax Assets, Valuation Allowance	400,000	300,000
Foreign Tax Jurisdiction [Member] | Subsidiary, Female Health Company Limited [Member]
Deferred Tax Assets, Valuation Allowance	3,200,000	$ 3,200,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	70,000,000
State and Local Jurisdiction [Member] | Tax Year, 2024 to 2043 Expirations [Member]
Operating Loss Carryforwards	35,600,000
State and Local Jurisdiction [Member] | Tax Year, Not Subject to Expiration [Member]
Operating Loss Carryforwards	$ 34,400,000

Note 14 - Income Taxes - Schedu

Note 14 - Income Taxes - Schedule of Income (Losses) Before Income Tax, Domestic and Foreign (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Loss before income taxes	$ (37,076,325)	$ (92,672,486)
Domestic Tax Jurisdiction [Member]
Loss before income taxes	(37,791,920)	(90,522,387)
Foreign Tax Jurisdiction [Member]
Loss before income taxes	$ 715,595	$ (2,150,099)

Note 14 - Income Taxes - Sche_2

Note 14 - Income Taxes - Schedule of Reconciliation (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income tax benefit at U.S. federal statutory rates	$ (7,786,028)	$ (19,461,222)
Income tax benefit at U.S. federal statutory rates, percent	21%	21%
State income tax benefit, net of federal benefits	$ (602,861)	$ (1,506,855)
State income tax benefit, net of federal benefits, percent	1.60%	1.60%
Non-deductible expenses	$ 200,233	$ 330,281
Non-deductible expenses, percent	(0.50%)	(0.30%)
U.S. research and development tax credit	$ 655,526	$ 178,378
U.S. research and development tax credit, percent	(1.80%)	(0.20%)
Effect of foreign income tax rates	$ 292,970	$ 454,808
Effect of foreign income tax rates, percent	(0.80%)	(0.50%)
Effect of common stock options exercised	$ 13,339	$ 180,847
Effect of common stock options exercised, percent	0%	(0.20%)
Effect of global intangible low-taxed income	$ 500,613	$ (24,691)
Effect of global intangible low-taxed income, percent	(1.40%)	(0.00%)
Change in valuation allowance	$ 7,367,014	$ 20,205,808
Change in valuation allowance, percent	(19.90%)	(21.80%)
Other, net	$ 84,295	$ 122,852
Other, net, percent	(0.20%)	(0.10%)
Income tax expense	$ 725,101	$ 480,206
Income tax expense, percent	(2.00%)	(0.50%)

Note 14 - Income Taxes - Sche_3

Note 14 - Income Taxes - Schedule of Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Deferred – U.S.	$ 0	$ (63,426)
Subtotal, Deferred	367,182	177,499
Current – U.S.	0	(8,624)
Subtotal, Current	357,919	302,707
Income tax expense	725,101	480,206
UNITED KINGDOM
Deferred – Foreign	423,127	262,612
MALAYSIA
Deferred – Foreign	(55,945)	(21,687)
Current – Malaysia	$ 357,919	$ 311,331

Note 14 - Income Taxes - Sche_4

Note 14 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Deferred tax assets:
Federal net operating loss carryforwards	$ 34,485,560	$ 29,100,871
State net operating loss carryforwards	3,662,406	3,322,715
Foreign net operating loss carryforwards – U.K.	15,303,535	15,749,809
Foreign capital allowance – U.K.	184,779	174,748
Share-based compensation	10,198,368	7,896,221
U.S. research and development tax credit carryforward	7,647,885	8,303,411
U.S. research and development expense	8,969,277	9,771,166
Accrued compensation	911,277	190,397
Interest expense	2,241,652	2,602,890
U.S. credit loss provision	885,562	885,562
Gross deferred tax assets	85,238,075	78,293,666
Valuation allowance for deferred tax assets	(72,502,102)	(65,135,088)
Net deferred tax assets	12,735,973	13,158,578
Deferred tax liabilities:
Change in fair value of derivative liability	(395,736)	(449,812)
Covenant not-to-compete	0	(1,347)
Net deferred tax liabilities	(395,736)	(451,159)
Net deferred tax asset, total	12,340,237	12,707,419
UNITED KINGDOM
Deferred tax assets:
Share-based compensation	299,868	217,821
Other, net	2,500	2,500
Deferred tax liabilities:
Net deferred tax asset, total	12,280,245	12,703,373
MALAYSIA
Deferred tax assets:
Other, net	59,992	4,046
Deferred tax liabilities:
Net deferred tax asset, total	59,992	4,046
UNITED STATES
Deferred tax assets:
Other, net	$ 385,414	$ 71,509

Note 14 - Income Taxes - Sche_5

Note 14 - Income Taxes - Schedule of Deferred Assets (Liabilities) Classification (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Long-term deferred tax asset	$ 12,340,237	$ 12,707,419
UNITED KINGDOM
Long-term deferred tax asset	12,280,245	12,703,373
MALAYSIA
Long-term deferred tax asset	$ 59,992	$ 4,046

Note 15 - Sale of ENTADFI Ass_2

Note 15 - Sale of ENTADFI Assets (Details Textual)							1 Months Ended	12 Months Ended
	Nov. 26, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 24, 2024 shares	Apr. 24, 2024 USD ($)	Sep. 29, 2023 USD ($) $ / shares shares	Apr. 19, 2023 USD ($)	Oct. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Proceeds from Sale of Productive Assets								$ 304,536	$ 7,000,000
Noncash or Part Noncash Divestiture, Amount of Consideration Received								918,372	0
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal								1,222,908	5,723,623
ONCO [Member] | Preferred Shares Converted to Common Shares [Member]
Conversion of Stock, Shares Converted (in shares) | shares			142,749
Reverse Stock Split [Member] | ONCO [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			40
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement [Member]
Disposal Group, Including Discontinued Operation, Consideration						$ 20,000,000
Proceeds from Sale of Productive Assets						6,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement [Member] | Promissory Notes Receivable, Due September 30, 2023 [Member]
Disposal Group, Including Discontinued Operation, Consideration						4,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement [Member] | Promissory Notes Receivable, Due April 19, 2024 [Member]
Disposal Group, Including Discontinued Operation, Consideration		$ 3,500,000				5,000,000		$ 3,500,000
Debt Instrument, Interest Rate, Stated Percentage		10%						10%
Proceeds from Sale and Collection of Receivables								$ 300,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement [Member] | Promissory Notes Receivable, Due April 19, 2024 [Member] | Subsequent Event [Member]
Proceeds from Sale and Collection of Receivables							$ 400,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement [Member] | Promissory Notes Receivable, Due September 30, 2024 [Member]
Disposal Group, Including Discontinued Operation, Consideration						5,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement [Member] | Milestone Receivable [Member]
Disposal Group, Including Discontinued Operation, Consideration						$ 80,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement, Amended [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares					$ 1,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares					$ 0.5254
Preferred Stock, Convertible, Shares Issuable (in shares) | shares					5,709,935
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal								$ 1,200,000	$ 5,700,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement, Amended [Member] | BWV Preferred Stock [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares) | shares					3,000
Noncash or Part Noncash Divestiture, Amount of Consideration Received					$ 900,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement, Amended [Member] | Promissory Notes Receivable, Due September 30, 2023 [Member]
Proceeds from Collection of Notes Receivable					1,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement, Amended [Member] | Promissory Notes Receivable, Due September 30, 2023 [Member] | Note Receivable, Settlement Terms [Member]
Disposal Group, Including Discontinued Operation, Consideration					4,000,000
Proceeds from Collection of Notes Receivable					$ 1,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement, Amended [Member] | Promissory Notes Receivable, Due April 19, 2024 [Member]
Proceeds from Collection of Notes Receivable				$ 50,000
Notes Receivable, Percentage of Revenues		25%		15%
Notes Receivable, Percentage of Net Proceeds		20%		10%
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement, Amended [Member] | Promissory Notes Receivable, Due April 19, 2024 [Member] | Subsequent Event [Member]
Notes Receivable, Percentage of Net Proceeds	25%
Notes Receivable, Covenant, Minimum Net Capital Raised	$ 97,000

Note 17 - Employee Benefit Pl_2

Note 17 - Employee Benefit Plans (Details Textual) - USD ($)				1 Months Ended	12 Months Ended
	Jan. 01, 2025	Jan. 01, 2019	Jan. 01, 2018	Mar. 31, 2014	Sep. 30, 2024	Sep. 30, 2023
The 401(k) Plan [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match			100%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay			6%
Defined Contribution Plan, Cost					$ 42,000	$ 600,000
The 401(k) Plan [Member] | Forecast [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4%
Pension Plan [Member] | Foreign Plan [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay		4%		3%
Defined Contribution Plan, Cost					$ 29,000	$ 29,000